{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:25:46Z","timestamp":1787811946498,"version":"build-2784847793"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005977","name":"KAISER PERMANENTE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ygyno.2022.10.001","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T19:16:25Z","timestamp":1665256585000},"page":"467-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system"],"prefix":"10.1016","volume":"167","author":[{"given":"C. Bethan","family":"Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hoodfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Karlea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kobelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janise","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Kushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2022.10.001_bb0005","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1097\/AOG.0000000000002296","article-title":"Practice bulletin no 182: hereditary breast and ovarian cancer syndrome","volume":"130","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2022.10.001_bb0010","unstructured":"National Comprehensive Cancer Network, Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2022 - August 11, 2021). Accessed June 2, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf"},{"issue":"9","key":"10.1016\/j.ygyno.2022.10.001_bb0015","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ygyno.2022.10.001_bb0020","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2022.10.001_bb0025","first-page":"787","article-title":"What\u2019s new in genetic testing for cancer susceptibility?","volume":"30","author":"Plichta","year":"2016","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"10.1016\/j.ygyno.2022.10.001_bb0030","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes - association analysis in more than 113,000 women","volume":"384","author":"Breast Cancer Association Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.10.001_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00066","article-title":"Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women","volume":"1","author":"Kurian","year":"2017","journal-title":"JCO Precis. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.001_bb0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.10.001_bb0045","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2022.10.001_bb0050","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/bjc.2015.78","article-title":"Age-specific risk of breast cancer in women with neurofibromatosis type 1","volume":"112","author":"Seminog","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"17","key":"10.1016\/j.ygyno.2022.10.001_bb0055","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive cancer associations in patients with neurofibromatosis type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.10.001_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100235","article-title":"Impact of deleterious variants in other genes beyond BRCA1\/2 detected in breast\/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge","volume":"6","author":"Bono","year":"2021","journal-title":"ESMO Open."},{"issue":"7","key":"10.1016\/j.ygyno.2022.10.001_bb0065","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.10.001_bb0070","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/AOG.0000000000002531","article-title":"Effects of cancer genetic panel testing on at-risk individuals","volume":"131","author":"Frost","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"11","key":"10.1016\/j.ygyno.2022.10.001_bb0075","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients","volume":"16","author":"LaDuca","year":"2014","journal-title":"Genet. Med."},{"issue":"13","key":"10.1016\/j.ygyno.2022.10.001_bb0080","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.2015.63.7454","article-title":"Panel testing for familial breast cancer: calibrating the tension between research and clinical care","volume":"34","author":"Thompson","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2022.10.001_bb0085","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41436-021-01172-3","article-title":"ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Miller","year":"2021","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.001_bb0090","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","article-title":"Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers","volume":"148","author":"Chai","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.001_bb0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/tbj.12521","article-title":"Surgical decision making in the BRCA-positive population: institutional experience and comparison with recent literature","volume":"22","author":"Flippo-Morton","year":"2016","journal-title":"Breast J."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.001_bb0100","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ygyno.2013.12.014","article-title":"Risk management options elected by women after testing positive for a BRCA mutation","volume":"132","author":"Garcia","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.10.001_bb0105","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1399-0004.2009.01329.x","article-title":"Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing","volume":"77","author":"Skytte","year":"2010","journal-title":"Clin. Genet."},{"issue":"10","key":"10.1016\/j.ygyno.2022.10.001_bb0110","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1245\/s10434-017-5976-2","article-title":"Differences among a modern cohort of BRCA mutation carriers choosing bilateral prophylactic mastectomies compared to breast surveillance","volume":"24","author":"Gilbert","year":"2017","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.001_bb0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-018-5057-7","article-title":"Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE)","volume":"174","author":"Henry","year":"2019","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822018571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822018571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:03:36Z","timestamp":1758773016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822018571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0090825822018571"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}